EGFR and asthenia: In a retrospective analysis of data from three trials of first-line chemotherapy plus the anti-EGFR antibody panitumumab in RAS-wild-type mCRC, the onset of new tumor-related symptoms, defined as new opiate use, weight loss, anemia, asthenia, and decline in ECOG PS, was delayed by achieving ETS, regardless of the treatment regimen received [36].